Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of ...